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Emergence of serogroup B meningococci of clonal com-
plex sequence type (ST) 41/44 can cause high levels of dis-
ease, as exempliﬁ  ed by a recent epidemic in New Zealand. 
Multiplication of annual incidence rates (3.1 cases/100,000 
population) of meningococcal disease in a deﬁ  ned  Ger-
man region, the city of Aachen and 3 neighboring countries 
(Greater Aachen) prompted us to investigate and determine 
the source and nature of this outbreak. Using molecular 
typing and geographic mapping, we analyzed 1,143 strains 
belonging to ST41/44 complex, isolated from persons with 
invasive meningococcal disease over 6 years (2001–2006) 
from 2 German federal states (total population 26 million) 
and the Netherlands. A spatially slowly moving clone with 
multiple-locus variable-number tandem repeat analysis 
type 19, ST42, and antigenic proﬁ  le B:P1.7–2,4:F1–5 was 
responsible for the outbreak. Bactericidal activity in serum 
samples from the New Zealand MeNZB vaccination cam-
paign conﬁ  rmed vaccine preventability. Because this glob-
ally distributed epidemic strain spreads slowly, vaccination 
efforts could possibly eliminate meningococcal disease in 
this area.  
O
ur work describes the epidemiology of invasive 
meningococcal disease (IMD) caused by meningo-
cocci of clonal complex (cc) 41/44 in the Netherlands and 
the 2 bordering German states Lower Saxony and North-
Rhine-Westphalia during 2001–2006. Neisseria meningitis 
is a gram-negative bacterium that occasionally causes inva-
sive disease in humans, primarily meningitis or sepsis (1). 
Notwithstanding low incidence rates in most industrialized 
countries, IMD remains a serious public health problem be-
cause of its predilection for affecting young persons and its 
≈10% death rate despite antimicrobial drug treatment. In 
contrast to the meningitis belt in Africa, where epidemic 
waves cause incidence rates up to 300 cases/100,000 popu-
lation (2), epidemics or case clusters are rare in industrial-
ized countries (3). Meningococci are antigenically diverse 
bacteria that can be divided into 12 serogroups by varia-
tion of their polysaccharide capsules. Despite increased 
ﬁ  ndings of serogroup C meningococci in several countries, 
serogroup B has clearly controlled the epidemiology of 
IMD in western Europe for the past 20 years. Dominance 
of serogroup B has further been compounded by numerous 
vaccination campaigns with polysaccharide C conjugate 
vaccine leading to a decline in serogroup C disease (4). Un-
fortunately, the serogroup B polysaccharide is an unsuit-
able vaccine antigen because of poor immunogenicity. De-
spite substantial progress in the development of vaccines 
based on membrane-associated antigens (5,6), a universal 
vaccine against meningococci has yet to be licensed.
Typing of N. meningitidis is critical for tracking trans-
missions and recognition of disease clusters. In recent 
years, focus has shifted to portable molecular typing meth-
ods with high discriminatory power. The preferred method 
for sequence-based typing of meningococci is multilocus 
sequence typing (MLST) (7), which enables identiﬁ  cation 
of strains belonging to hypervirulent clonal complexes re-
sponsible for most cases of the invasive disease (8). MLST 
is complemented by antigen sequence typing of the variable 
regions of the outer membrane proteins PorA and FetA (9). 
Moreover, multiple-locus variable-number tandem repeat 
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analysis (MLVA), which shows slightly higher discrimina-
tory ability than MLST (10), represents a recent addition to 
the arsenal of portable typing methods for N. meningitidis.
Differences in the antigenic makeup of meningococcal 
clonal complexes (cc) (11) likely inﬂ  uence reported dis-
parities in spatiotemporal spread. Whereas strains belong-
ing to the multilocus sequence type (ST) 5 complex (cc5/
subgroup III) (12) and ST11 complex (cc11/ET-37 com-
plex) (13) depend on migration to survive, strains of the 
ST41/44 complex (cc41/44/lineage 3) have been described 
as causing stationary and persistent hyperendemic disease, 
as exempliﬁ  ed by the New Zealand serogroup B epidemic, 
which lasted more than a decade (14).
cc41/44 is a large hypervirulent complex that revolves 
around 2 STs instead of 1 central ST, namely ST41 and 
ST44 (15). It was ﬁ  rst described in the Netherlands in the 
1980s (16), where it caused a substantial increase in disease 
incidence (17,18). Subsequently, this lineage was reported 
in Belgium in the early 1990s (19), then New Zealand since 
1991 (14). In New Zealand an epidemic with incidences up 
to 17.4 cases/100,000 population in 2001 prompted an im-
munization campaign with custom made outer-membrane-
vesicle vaccine MeNZB (Novartis Vaccines and Diagnos-
tics, Siena, Italy) (20).
By using cluster detection software SaTScan (www.
satscan.org) (21) for laboratory surveillance of IMD at 
the German Reference Center for Meningococci (22), we 
showed spatial concentrations of meningococci with anti-
gen sequence type B:P1.7–2.4:F1–5 (serogroup B, PorA 
VR1 7–2, PorA VR2 4, and FetA VR 1–5), strongly associ-
ated with cc41/44 (11), around the German city of Aachen 
near its border with the Netherlands. The annual incidence 
rate rose to 3.1/100,000 in 2005 among a population of 
1.1 million living in Aachen and 3 neighboring counties 
(Greater Aachen; Figure 1).
We mapped the epidemiology of IMD caused by 
cc41/44 meningococci in the Netherlands and 2 neighboring 
German states, Lower Saxony and North-Rhine-Westphalia, 
during 2001–2006. Furthermore, we characterized the clone 
responsible for the upsurge of IMD in Greater Aachen.
Materials and Methods
Bacterial Strains
All N. meningitidis strains analyzed in this study were 
isolated from patients with IMD. One isolate was included 
for each patient. During 2001–2006, a total of 239 strains 
collected by NRZM and 904 isolates collected by the Neth-
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Figure 1. Distribution of cc41/44 Neisseria meningitidis strains in Germany and the Netherlands during 2001–2006 with positively 
associated multiple-locus variable-number tandem repeat analysis (MLVA) and multilocus sequence types (MLST). A) Distribution of MLVA 
type (MT) 19/MLST (ST) 42 strains (red triangles). Full green circles represent non–MT19/ST42 strains. Black rectangle delineates the 
area magniﬁ  ed in panel B. B) Area encompassing Limburg (orange shading) and Greater Aachen (blue shading). C–E) Spatial distribution 
of other overrepresented MT/ST variants: MT27/ST40 (blue triangles); MT30/ST40 (orange triangles); MT78/ST1374 (purple triangles).RESEARCH
erlands Reference Laboratory for Bacterial Meningitis, 
Academic Medical Center, Amsterdam, North Holland, the 
Netherlands) were included in the study. Only strains of 
serogroup B with positive ampliﬁ  cation of cc41/44-speciﬁ  c 
restriction-modiﬁ  cation system Neisseria meningitis (Nme)
SI (17) and subsequent conﬁ  rmation of cc41/44 by MLST 
were included. In addition, 51 serogroup B, NmeSI–pos-
itive strains obtained from the Netherlands in 1985 were 
analyzed as a historic reference. NZ98/254 is the meningo-
coccal strain used to make MeNZB (Novartis Vaccines and 
Diagnostics) (20).
Typing of Meningococci
MLST (7) and antigen sequence typing of PorA (23) 
and FetA (24) were performed according to published pro-
tocols. MLVA targeting 8 loci was performed according to 
the method described by Schouls et al. (10). However, no-
menclature of repeat proﬁ  les has been changed since their 
original description; current MLVA types (MTs) and con-
version tables are available from www.mlva.net. Unique 
combinations of serogroup, PorA variable region 1 (VR1), 
PorA variable region 2 (VR2), and variable region of FetA 
(FetA VR) were termed ﬁ  ne types. Simpson diversity in-
dices (DIs) of the above typing schemes used alone or in 
combination were calculated as outlined by Hunter and 
Gaston (25). Ninety-ﬁ  ve percent conﬁ  dence intervals (CIs) 
of DI were determined by using the percentile bootstrap 
method after 1,000 replicates implemented in the package 
boot, written by A. Canty and B. Ripley for R (R Founda-
tion for Statistical Computing, Vienna, Austria), version 
2.8.0 (www.r-project.org).
Spatiotemporal Data
Geographic coordinates (map datum World Geodetic 
System [WGS] 84) were derived from German and Dutch 
postal codes. Yearwise categorization of data was based on 
the dates of sampling or dates of entry if sampling infor-
mation was not available. Maps (Figure 1) were generated 
by using Regiograph 8 (GfK GeoMarketing GmbH, Bruch-
sal, Germany). Yearwise spatial densities of MT19/ST42 
strains in the study area (Figure 2) were calculated by using 
Spatstat, version 1.15–1, created by A. Baddeley and R. 
Turner for the statistical environment R.
Statistical Analyses
Covariation among MTs and STs was assessed by us-
ing the Jaccard similarity coefﬁ  cient (J), as described by 
Rhee et al. (26), with slight modiﬁ  cations. Brieﬂ  y, for any 
combination of MT and ST, the J coefﬁ  cient is the ratio be-
tween the number of strains belonging to the combination 
in question divided by the number of strains sharing either 
MT or ST. It is calculated as J = NVS/(NVS + NV0 + N0S), 
where NVS represents the number of strains with a certain 
MT and ST, NV0 is the number of strains with the same MT 
but another ST, and N0S is the number of strains with the 
same ST but another MT. Observed J and expected Jaccard 
coefﬁ  cients (JEXP) were compared for each combination, as-
suming random coupling of types. JEXP was calculated as 
the mean J coefﬁ  cient after 2,000 random rearrangements 
of the MT and ST vector (consisting of Boolean values in-
dicating presence or absence of types). p values testing the 
equality of J and JEXP for any combination of MT and ST 
were derived by using an inverse quantile function based 
on the distribution of 105 bootstrap replicates. We used 
the Holm method to control the familywise error rate for 
multiple hypothesis testing (27). The Pearson χ2 test was 
calculated with R.
Serum Bactericidal Assay
German strain DE9686 (B:P1.7–2,4:F1–5:ST42:
MT19) isolated in 2004 from a patient of IMD in Aachen 
was used as the target strain in a validated serum bacte-
ricidal assay (28). Because the serum complement source 
used in the New Zealand trials contained interfering anti-
bodies against strain DE9686, an alternative serum comple-
ment source for strain DE9686 was found from a range of 
adult volunteers. Prevaccination and postvaccination serum 
samples from 20 persons, 18 months–12 years of age, who 
had been vaccinated with 3 doses of MeNZB vaccine (No-
vartis Vaccines and Diagnostics) during the New Zealand 
trials, were tested against the German target strain, DE9686 
by using the new serum complement source. Interpolated 
titer values were measured by using a formula that calcu-
lates the level of antibodies on the basis of percentage kill 
immediately on either side of the 50% cutoff (28).
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Figure 2. Temporal progression of the proportion of MT19/ST42 
meningococcal strains in the Netherlands and the German study 
region (North-Rhine-Westphalia and Lower Saxony), 2001–2006. 
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Results
Performance of Typing Methods
All 1,143 strains were tested by MLVA, MLST, and 
antigen sequence typing. Fine typing, i.e., serogroup, PorA 
VR1, PorA VR2, and FetA VR type showed 195 unique 
types, which translates to a low DI of 0.752 (95% CI 
0.726–0.778). MLVA and MLST distinguished 232 (DI 
0.942, 95% CI 0.933–0.948) and 222 (DI 0.893, 95% CI 
0.879–0.905) types, respectively, conﬁ   rming the higher 
discriminatory ability of MLVA when compared with 
MLST. Both neutral typing methods (MLST and MLVA) 
provided higher discrimination than antigen sequence typ-
ing. Finally, combination of MLVA and MLST yielded 504 
unique MLVA-MLST (MT-ST) types, demonstrating the 
extremely ﬁ  ne-grained resolution (Simpson’s index 0.985, 
95% CI 0.981–0.987) attained for the binational collection 
of cc41/44 N. meningitidis strains.
Covariation and Spatial Pattern of MLVA-MLST 
Combinations
Covariation was computed for MTs and STs that were 
identiﬁ  ed at least 10 times. The average J coefﬁ  cient for 
observed combinations was low (0.06), suggesting a lim-
ited overlap between MLVA and MLST. After controlling 
the familywise error rate at <0.01, four MT-ST combina-
tions showed marked positive association, indicating recent 
clonal expansion: MT19/ST42, MT27/ST40, MT30/ST40, 
and MT78/ST1374. In contrast, 3 combinations occurred 
signiﬁ  cantly less frequently than expected: MT27/ST41, 
MT30/ST41, and MT78/ST41 (Table 1). Geographic coor-
dinates were available for 1,102 (96.4%) of 1,143 strains. 
Two of the positively linked MT-ST combinations showed 
evidence for clustering: MT78/ST1374 around the Dutch 
city of Den Haag and, more explicitly, MT19/ST42 in 
Greater Aachen (Figure 1, panels A and B).
Clustering of MT19/ST42 Meningococci
Strains with MT19/ST42 occurred almost exclusive-
ly on the German side of Greater Aachen: of 50 German 
MT19/ST42 strains, only 8 were isolated from outside this 
region, all but 1 occurred within 100 km of Aachen (Fig-
ure 1, panel B, p<2.2 × 10–16, χ2 test). A similar, albeit less 
marked concentration, was observed for the Netherlands 
regarding the province of Limburg: 15 of 37 MT19/ST42 
(40.1%) strains with corresponding regional data originated 
from this province, compared with 97 (11.7%) of 826 other 
cc41/44 isolates (p = 1.2 × 10–6, χ2 test). From a total of 
91 MT19/ST42 strains, 81 (89.0%) were B:P1.7–2.4:F1–5. 
In contrast to the 41 Dutch MT19/ST42 isolates, which 
displayed 7 different ﬁ  ne types with 76% dominance of 
B:P1.7–2.4:F1–5, all 50 German MT19/ST42 isolates were 
B:P1.7–2,4:F1–5. Mean annual incidence rates of MT19/
ST42 per 100,000 population in the Netherlands, the Ger-
man states Lower Saxony and North-Rhine Westpahlia (in-
cluding Greater Aachen), and Greater Aachen were 0.04, 
0.03, and 0.63, respectively. In conclusion, most of type 
MT19/ST42 strains were isolated from Germany (50/91 
strains), where they displayed a higher degree of clustering 
and antigenic uniformity.
Temporal Trends and Migration of the Outbreak Strain
The total number of cc41/44 isolates declined from 
257 in 2001 to 137 in 2006. The proportion of MT19/
ST42 strains was higher in the German region in every year 
from 2001 to 2006 and peaked at 0.27 in 2004 (Figure 2. 
This clone was the most common MT-ST combination in 
the German region during 2001–2006, as opposed to the 
Netherlands, where the most numerous combinations per 
year were MT19/ST41 (2001), MT19/ST42 (2002), MT19/
ST41 (2003), MT18/ST41 (2004), MT18/ST41 (2005), 
and MT19/ST41 together with MT18/ST41 (2006). Fur-
thermore, the proportion of MT19/ST42 in the German 
area never fell below 0.15, whereas in the Netherlands it 
decreased to 0.01 in 2006 (Figure 3) because of slow east-
ward migration from the Dutch province of Limburg to-
ward Greater Aachen (Figure 3). A historic sample from 
the Netherlands from 1985 yielded 1 MT19/ST42 strain out 
of 51 (proportion 1.96%, 95% CI 0.00–11.79), indicating 
either reoccurrence of this type over >2 decades or inde-
pendent reassociation of alleles.
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Table 1. Positively and negatively correlating MLVA-MLST pairs, Neisseria meningitis clone, Greater Aachen Region, Germany, 2001–
2006*
Association MT ST  N NEXP N (MT)  N (ST)  J JEXP p value† 
19 42 91 38 209 209 0.2783 0.1013 0
30 40 19 3 38 82 0.1881 0.0235 0
78 1374 25 2 54 39 0.3676 0.0199 0
Positive
27 40 18 4 59 82 0.1452 0.032 0.00002
27 41 3 16 60 292 0.0086 0.0462 0
30 42 1 7 38 209 0.0041 0.0287 0
Negative
78 41 4 14 54 292 0.0117 0.0416 0.00004
*MLVA, multilocus variable tandem repeat analysis; MLST, multilocus sequence type; MT, MLVA type; ST, multilocus-sequence type, N, no. strains with 
MT and ST; NEXP, expected number of strains with MT and ST; N (MT), no.strains with MT; N (ST), no. strains with ST; J, Jaccard index; JEXP, expected 
Jaccard index 
†2-tailed. RESEARCH
Age Distribution of Case-Patients
Age information was available for 1,140 of 1,143 
(99.7%) case-patients. IMD caused by MT19/ST42 oc-
curred more commonly among patients >10 years of age 
(p = 4.2× 10–4, χ2 test). A plot of the age distribution of 
cases due to meningococci of cc41/44 illustrates a bimodal 
pattern considered typical for IMD (Figure 4). Neverthe-
less, cases caused by clone MT19/ST42 disproportionately 
affected adolescents, with no difference between the Neth-
erlands and Germany (p = 0.90, χ2). This positive shift is 
consistent with an epidemic age pattern described in the 
1970s during an epidemic wave of meningococcal disease 
in Finland (29) and during the 1980s in the Netherlands 
(30).
Serum Bactericidal Antibody Responses
against DE9686
Typing methods (MLVA, MLST, “ﬁ  ne typing”) could 
not distinguish NZ98/254 from DE9686 (B:P1.7–2.4:F1–
5:ST42:MT19). Serum bactericidal antibody responses 
of persons vaccinated with MeNZB suggested protective 
levels (i.e., >8) in all serum samples. These samples were 
tested in a serum bactericidal assay with DE9686 as a target 
strain. The test determines the maximal dilution at which 
killing activity of tested serum can be observed (Table 2). 
A 4-fold rise in titer was observed in the postvaccination 
sample for all (10/10) toddlers (18–24 months of age) and 
8 of 10 schoolchildren (8–12 years of age). Only titers in 
2 persons with the highest prevaccination titers (189 and 
229) rose <4-fold after vaccination with MeNZB (Novartis 
Vaccines and Diagnostics).
Discussion
Our main goals were to identify the clone causing 
the rise in incidence rate in Greater Aachen and to eluci-
date whether increased disease activity in Germany rep-
resented local emergence or cross-border spread from the 
Netherlands, which had experienced a steep rise in IMD 
caused by cc41/44 since 1980 (18). Tracking of variants 
within cc41/44 necessitated a high level of discrimination, 
achieved by the combination of typing methods MLVA 
and MLST (DI 0.985). Geographic mapping showed it was 
only the latter pairing of techniques that sharply delineated 
a spatial accumulation of MT19/ST42 meningococci in the 
region that had seen increase of disease rate (Figure 1). 
The spread of the outbreak clone differed upon introduc-
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Figure 3. Yearwise spatial 
distribution of MT19/ST42 
strains within the study 
region in Germany during 
2001–2006. Color-coded 
values represent estimates 
of the intensity function 
underlying the point pattern 
data. Gray circle marks the 
city of Aachen; the white 
line represents the border 
between the Netherlands 
and Germany.Meningococcal Outbreak, Greater Aachen Region, Germany
tion into Germany, where it caused high levels of disease 
in a conﬁ  ned area. The distinct level and high spread of 
disease may suggest the presence of regionally speciﬁ  c, 
as yet unknown, factors contributing to its emergence. 
Because behavior-related risk factors promote acquisition 
of IMD in adolescents (31), locally differing traditions in 
Germany, possibly related to carnival festivities in sea-
sons with high incidence (32), may have contributed to the 
outbreak. Nevertheless, clustering was also present, albeit 
less abundantly, in the Dutch province of Limburg. Higher 
antigenic diversity and discrete eastward motion indicate 
the clone’s longer history in the Netherlands, where it had 
failed to cause an epidemic, possibly due to population im-
munity elicited by long-lasting exposure to related variants 
of cc41/44 since the 1980s.
Although clusters of cases tend to be short-lived in 
industrialized countries (33), the geographic concentra-
tion of the outbreak clone was observed during the whole 
study period (Figure 3). This spatial stability might be 
promoted by the clone’s more efﬁ  cient evasion of in-
duction of mucosal immunity. Notably, antigenic varia-
tion of the outbreak clone was limited and dominated 
by B:P1.7–2.4:F1–5 (89%). Lower antibody avidity ob-
served after vaccination with OMVs containing P1.7–2.4 
(34) suggests that this PorA-type evokes a less potent im-
mune response, possibly leading to decreased protection 
against acquisition of carriage. Studies conﬁ  rming this 
hypothesis, however, have not been published. Moreover, 
the higher diversity unveiled by neutral typing techniques 
compared with antigen sequence typing could suggest 
positive selection for strains achieving immune escape 
because of their antigenic proﬁ  le.
There was a signiﬁ  cant shift toward older age of pa-
tients infected by MT19/ST42 meningococci, consistent 
with observations before and during epidemics (29,30). A 
recent report demonstrates an overrepresentation of menin-
gococci harboring the meningococcal disease associated is-
land among young adults with IMD, possibly indicating its 
contribution to invasive disease in this age group (35). Fre-
quent isolation of presumably more virulent meningococci, 
such as MT19/ST42, from adolescents might be explained 
by the hypotheses that 1) fewer virulence determinants are 
required to cause invasion in infants, hence strains of lower 
invasiveness are recovered in higher proportions among 
them, and 2) invasiveness represents a smaller penalty for 
highly transmissible strains in persons with abundant so-
cial contacts (36), leading to their preferential circulation 
among older age groups.
In an analysis of meningococci across several clonal 
complexes, Schouls et al. obtained similar groupings by 
MLVA and MLST (10). To identify type pairs deviating 
from their expected occurrence within strains of this study, 
which pertained to a single clonal complex (cc41/44), we 
computed the degrees of overlap (represented by J coef-
ﬁ  cients) of observed combinations between MTs and STs. 
The mean overlap was low (0.06), and the number of most 
combinations did not differ signiﬁ  cantly from the expected, 
suggesting random association in most types and highlight-
ing the complementary nature of MLST and MLVA for 
cc41/44. The added value of combining these typing meth-
ods is also reﬂ  ected in the signiﬁ  cantly higher DI attained. 
Positively associated combinations could reﬂ  ect linkage 
disequilibrium in concordance with an epidemic population 
concept (37), which attributes disequilibrium to transient 
multiplication of successful variants doomed to dissipate 
within years, secondary to recombination. Nevertheless, 
recovery of MT19/ST42 over >20 years favors concepts 
that accommodate the observed excessive stability, e.g., 
proposed in models including interstrain competition (36). 
On the other hand, strains with a negative association might 
indicate low epidemic potential. All sequence types recov-
ered from covariation analysis (ST40, ST42, and ST41, 
ST1374) represent (sub)group founders within cc41/44, at-
tributed higher transmissibility and ﬁ  tness due to persistent 
recovery in both carrier and invasive collections (36). Al-
though observed presence of founder STs could be due to 
biased selection of STs for covariation analysis (only types 
occurring at least 10 times were included), the clear under-
representation of some MTs belonging to mentioned STs 
suggests that at least virulence within these founder STs is 
not equally distributed (Table 1).
The following observations support the hypothesis 
that meningococci of the clone MT19/ST42 command 
exceptional epidemic potential: dramatic spatial concen-
tration displayed in Greater Aachen, concurrent rise of 
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Figure 4. Kernel density plots of age distribution of MT19/ST42 
case-patients compared with the rest of the ST41/44 complex. The 
vertical gray line indicates 10 years.RESEARCH
incidence in the area of clustering, and age-shift to older 
patients. Tendency to affect older persons has also been 
noted during epidemics (29,30) and in strains carrying a 
temperate bacteriophage associated with higher pathogenic 
potential (35). In addition, vaccine strain NZ98/254, which 
was used for generation of New Zealand’s MeNZB (Novartis 
Vaccines and Diagnostics) (38), was not distinguishable 
from German MT19/ST42 strains, demonstrating the 
clone´s emergence on separate continents.
By using paired serum samples from vaccinated tod-
dlers and schoolchildren (Table 2), we were able to show a 
striking similarity between the serum bactericidal antibody 
responses induced by the German epidemic strain and re-
sults obtained in New Zealand against NZ98/254 after vac-
cination of toddlers and 8–12 years of age (39,40). Similar 
to the New Zealand situation, a protective vaccine effect 
was strongly supported by the serum bactericidal antibody 
responses induced by the German strain. Moreover, be-
cause the VR2 epitope of PorA is the major target for im-
mune response elicited by MenZB (38), protection against 
most of the analyzed cc41/44 strains (58% have VR2 type 
4) can be assumed.
Although the marked concentration of meningococci 
with ﬁ  ne type B:P1.7–2.4:F1–5 continues to exist in western 
North-Rhine-Westphalia (www.episcangis.org), incidence 
rates have been decreasing since 2005; this decrease has 
suspended plans to implement a vaccine campaign. Never-
theless, the New Zealand experience (14) suggests that this 
clone may attain high-level endemicity, and continued close 
surveillance remains a task of high priority. Should regional 
incidences rise again, implementation of an immunization 
campaign with MeNZB should be considered.
Although we studied a large area involving 2 border-
ing countries, our study is limited. We did not include iso-
lates from asymptomatic carriers because of the logistic 
difﬁ  culties related to the collection of representative car-
riage samples that preceded or temporally coincided with 
outbreaks. Furthermore, the sampling period only covered 
6 years with 1 historic reference year because of the large 
number of strains. Finally, representative population im-
munity data were not available. Our study does, however, 
pave the ground for future epidemiologic and experimental 
work aimed at conﬁ  rming the distinct pathogenic potential 
of MT19/ST42 meningococci and unraveling the circum-
stances leading to their spatially distinct occurrence.
We tracked an outbreak clone that was causing con-
siderable disease activity on the border of 2 industrialized 
European countries by using highly discriminatory and 
portable typing techniques. These techniques could guide 
and improve the targeting of public health efforts, which 
may include vaccination, if incidence rates in North-Rhine-
Westphalia begin to rise again. 
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